Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Exclusion Criteria

• •Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
• •Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
• •Clinically significant gastrointestinal abnormalities
• •Prolongation of corrected QT interval (QTc) \> 480 msecs
• •History of any one or more cardiovascular conditions within the past 6 months prior to randomization
• •Cardiac angioplasty or stenting
• •Myocardial infarction
• •Unstable angina
• •Symptomatic peripheral vascular disease
• •* Class III or IV congestive heart failure
• •Poorly controlled hypertension
• •History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
• •Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
• •Evidence of active bleeding or bleeding diathesis.
• •Hemoptysis within 6 weeks prior to randomization.
• •Endobronchial metastases.
• •Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
• •Investigational or anti-VEGF anticancer therapy prior to study randomization.
• •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
• •Invasive malignancies that showed activity of disease within 5 years prior to randomization